The Company

Zymetech is an Icelandic biotechnology company specializing in research, purification and utilization of cold adopted enzymes from deep sea cod fish.

Zymetech ehf. was founded in 1999 by Dr. Jón Bragi Bjarnason and Dr. Ágústa Guðmundsdóttir, professors at the University of Iceland, who had gained deep understanding of the efficacy of enzymes from deep sea cod. Since then Zymetech has developed derma cosmetics, derma health products and medical devices that contain cod enzymes applied through the Penzyme® technology.
Zymetech extracts the enzymes from parts of the cod viscera that would otherwise be discarded.
Zymetech is fully owned by Enzymatica AB in Sweden.

Our Vision

To be the global leader in research, development and manufacturing of high-purity marine derived enzymes for use in cosmeceutical, medical device and pharmaceutical applications.

Quality Policy

We are committed to deliver effective high-quality products that fulfill regulatory requirements, and consistently meet expectations of our customers.

We are motivated through clear communication, process and training, to apply quality awareness in every detail of our work.

We look for opportunities to reflect, learn and act, so our operations can continuously improve.

Our History

  • 1999

    Zymetech is established from the University of Iceland by Prof. Jón Bragi Bjarnason and Prof. Ágústa Guðmundsdóttir. The PENZIM® skincare line is introduced.

  • 2000

    Zymetech develops the Penzyme® technology of stabilizing enzymes and activating them in formulations when applied on skin.

  • 2001

    Zymetech continues research of cod trypsin’s and development of innovative formulations for the health and beauty industries.

  • 2002

    Zymetech improves the PENZIM® skincare line utilizing Penzyme® Technology.

  • 2004

    Zymetech is awarded a patent on the use of cold adaptive proteases from coldwater marine organisms in specific formulations for therapeutic applications.

  • 2010

    Zymetech cooperates with Enzymatica AB in Sweden on developing mouth spray to fight common cold.

  • 2012

    Enzymatica AB in Sweden launches ColdZyme® mouth spray against the common cold. ColdZyme® formulation was developed by Zymetech using Penzyme® Technology.

  • 2014

    New Zymetech’s headquarters including research and production facilities opened in 2014.

  • 2015

    Zymetech launches PreCold® mouth spray in Iceland using the clinically proven ColdZyme® formulation.

  • 2015

    Zymetech is awarded the Icelandic Innovation Awards

  • 2016

    Enzymatica AB in Sweden acquires Zymetech to secure research know-how, patents, access to Penzyme® Technology and enzyme production capacity.

  • 2018

    Zymetech receives ISO 9001 certification

About Enzymatica AB

Enzymatica AB in Sweden is a life science company whose business concept is to offer effective help against some of the most common diseases where virus or bacteria play a decisive role. Enzymatica acquired Zymetech ehf. in April 2016 to create one company with full control of enzyme purification, Penzyme® Technology and patents. The merger builds a strong foundation for the continued rollout of ColdZyme® to the global marketplace. The focus of Zymetech in Iceland has strengthened as a center of excellence in R&D and purification of cod enzymes to be utilized in current and future products. Visit Enzymatica AB website.

Icelandic Innovation Award 2015

Zymetech was awarded the Icelandic Innovation Award 2015. The award is awarded to a company that has achieved outstanding results in creating value from innovation, research and knowledge.